

JACC Instructions for Authors

INTRODUCTION

The *Journal of the American College of Cardiology (JACC)* publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original research, experimental investigations with clear clinical relevance, state-of-the-art papers, and viewpoints. All manuscripts must be submitted online at www.jaccsubmit.org. Manuscript submissions should conform to the guidelines set forth in the “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations),” available online at www.icmje.org/recommendations and most recently updated in May 2023.

ARTICLE TYPES

JACC publishes the following manuscript types: Original Research, JACC State-of-the-Art Reviews, JACC Review Topics of the Week, JACC Historical Breakthroughs in Perspective, JACC Expert Panels, JACC Guideline Comparisons, JACC International, JACC Focus Seminars, Cardiovascular Medicine and Society, Research Letters, Letters to the Editor, and Fellows-in-Training & Early Career Sections. We also publish Editorial Comments for each Original Research article, although these are specifically invited by the editorial board and should not be submitted as unsolicited articles. In general, case reports will not be considered for publication.

Proposals for JACC State-of-the-Art Review, JACC Review Topic of the Week, JACC Historical Breakthroughs in Perspective, JACC Expert Panel, JACC Guideline Comparison, JACC International, and JACC Focus Seminar submissions should first be emailed to the editorial office at jacc@acc.org to determine if the editor is interested in considering your review for publication. The majority of reviews are solicited by the editors; however, proposals may be considered.

ORIGINAL RESEARCH. JACC Original Research should relate to cardiovascular science and medicine that may include studies conducted in humans or analyses of human data, or novel translational studies with direct clinical relevance that significantly advance the field.

- Word count: No more than 5,000 words. The word count includes text from introduction through the conclusion, references, and figure legends. It excludes abstract, clinical perspectives, and tables.
- Authors: No more than two corresponding authors; no more than two joint authors in any position
- Abstract: Structured with the following headings and no more than 250 words: Background, Objectives, Methods, Results, Conclusions. The abstract should present essential data in 5 paragraphs. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables. For general information on preparing structured abstracts, see “Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. *Ann Intern Med* 1990;113:69-76.”
- Condensed Abstract: Unstructured and no more than 100 words, stressing clinical implications
- Study limitations (required): Please include the limitations of your research at the end of the discussion section of your manuscript.
- Figure/Table Limit: None
- Central Illustration: Required
- Clinical Perspectives: Required
- Ethical Approval: Required. Please denote that your study received the proper ethical oversight in both your cover letter and the first paragraph of your Methods section. For manuscripts reporting data on human subjects, note institutional review board/ethics committee approval (or formal review and exemption), including the specific

name of the board or committee. For studies involving animal experiments, note that the study complied with all institutional and national requirements for the care and use of laboratory animals and, if applicable, received animal care and use committee approval. State the animal-handling protocol in your Methods.

- The Methods should note the geographical location and institution at which the research was performed.

JACC STATE-OF-THE-ART REVIEW. The Present and Future: JACC State-of-the-Art Review: As with all submissions to JACC, JACC State-of-the-Art Reviews should focus on the patient. From basic mechanisms to clinical manifestations and interventional approaches to global health implications, such manuscripts will focus on a contemporary, controversial, or translational topic with 4 to 5 major sections written by multiple authors or author groups.

- Word count: no more than 10,000 words (text from the introduction to the conclusion, including references and figure legends)
- Authors: No more than two corresponding authors; no more than two joint authors in any position
- Abstract: Unstructured and no more than 150 words
- Condensed Abstract: No more than 100 words, stressing clinical implications
- Figure Limit: None
- Table Limit: None
- Central Illustration: Required
- Clinical Perspectives: Not applicable

Please provide a list of 3-4 brief (85 characters, 15 words or fewer per bullet) bullet points that highlight the main messages of the review. The first bullet should provide the translational/clinical context or background that establishes the relevance or need for this review. The second bullet should speak to the main message and focus of the review, including any recommendations made by the authors. The final bullet should summarize where the field needs to move forward from this point.

Example:

- Cardiovascular aging leads to a progressive decline in function and structure.
- Calorie reduction and adjusted diurnal rhythm of feeding may help to prevent cardiovascular disease.
- Lowered intake of protein and nutritional modulation of the gut microbiome can be cardioprotective.
- Regular exercise, stress-reduction programs, and calorie-restriction mimetic medications can impact a healthy diet.

Please be sure you have obtained or will obtain permission for previously published tables, figures, or any material for which you cannot grant copyright. **NOTE: JACC State-of-the-Art Review submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC REVIEW TOPIC OF THE WEEK. The Present and Future: Review Topic of the Week: As with all submissions to JACC, JACC Review Topics of the Week should focus on the patient. They provide a literature review on a contemporary topic of basic, translational, or clinical science. Such manuscripts may be written by a single author or an author group.

- Word count: no more than 5,000 words (text from the introduction to the conclusion, including references and figure legends)
- Authors: No more than two corresponding authors; no more than two joint authors in any position
- Abstract: Unstructured and no more than 150 words
- Condensed Abstract: No more than 100 words, stressing clinical implications

- Figure Limit: None
- Table Limit: None
- Central Illustration: Required
- Clinical Perspectives: Not applicable

Please provide a list of 3-4 brief (85 characters, 15 words or fewer per bullet) bullet points that highlight the main messages of the review. The first bullet should provide the translational/clinical context or background that establishes the relevance or need for this review. The second bullet should speak to the main message and focus of the review, including any recommendations made by the authors. The final bullet should summarize where the field needs to move forward from this point.

Example:

- Cardiovascular aging leads to a progressive decline in function and structure.
- Calorie reduction and adjusted diurnal rhythm of feeding may help to prevent cardiovascular disease.
- Lowered intake of protein and nutritional modulation of the gut microbiome can be cardioprotective.
- Regular exercise, stress-reduction programs, and calorie-restriction mimetic medications can impact a healthy diet.

Please be sure you have obtained or will obtain permission for previously published tables, figures, or any material for which you cannot grant copyright. **NOTE: JACC Review Topic of the Week submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC HISTORICAL BREAKTHROUGHS IN PERSPECTIVE. Addressing the historical foundations of all aspects of cardiovascular practice, highlighting the important moments of breakthrough since its inception, and examining the recent literature in a comprehensive manner. Written by a group of experts who have substantially contributed to the developments being covered. No more than 10,000 words, including the references and figure legends. Follow the requirements listed for JACC State-of-the-Art Reviews (although they are not categorized as a JACC State-of-the-Art Review when published). Please include “: JACC Historical Breakthroughs in Perspective” at the end of the manuscript title. **NOTE: JACC Historical Breakthroughs in Perspective submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC EXPERT PANEL. Written by a group of key opinion leaders from multiple institutions and aiming to provide insight and guidance for a particular clinical situation wherein the Clinical Practice Guidelines are not substantial. Authors should be limited to those who have contributed substantially to the field. No more than 10,000 words or 5,000 words (as specified in the invitation), including the references and figure legends. Follow the requirements listed for JACC State-of-the-Art Review or JACC Review Topic of the Week, as appropriate (although they are not categorized as a JACC State-of-the-Art Review or JACC Review Topic of the Week when published). Please include “: JACC Expert Panel” at the end of the manuscript title. **NOTE: JACC Expert Panel submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC GUIDELINE COMPARISON. Review comparing the U.S. and European guidelines for a particular cardiovascular condition, highlighting areas where differences exist and discussing implications for clinical practice. Authors should be limited to key opinion leaders. No more than 5,000 words, including the references and figure legends. Follow the requirements listed for JACC Review Topic of the Week (although they are not categorized as a

JACC Review Topic of the Week when published). Please include “: JACC Guideline Comparison” at the end of the manuscript title. **NOTE: JACC Guideline Comparison submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC INTERNATIONAL. Focusing on cardiovascular care in other regions of the world. No more than 5,000 words, including the references and figure legends. Follow the requirements listed for JACC Review Topic of the Week (although they are not categorized as a JACC Review Topic of the Week when published). Please include “: JACC International” at the end of the manuscript title. **NOTE: JACC International submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

JACC FOCUS SEMINAR. Groups of related manuscripts commissioned to be published all in one issue or in consecutive issues. Each article is no more than 10,000 words or 5,000 words (as specified in the invitation), including the references and figure legends. Follow the requirements listed for JACC State-of-the-Art Review or JACC Review Topic of the Week, as appropriate (although they are not categorized as a JACC State-of-the-Art Review or JACC Review Topic of the Week when published). Please include “: JACC Focus Seminar” at the end of the manuscript title. **NOTE: JACC Focus Seminar submissions must be invited by the Editor-in-Chief or proposed to and approved by the Editor-in-Chief prior to submission. Please submit proposals to jacc@acc.org.**

CARDIOVASCULAR MEDICINE AND SOCIETY. These submissions should focus on the impact that government policy (federal, state, and local) and social considerations have on cardiovascular care and its global delivery systems. Such manuscripts may be written by a single author or an author group.

- Word count: No more than 2,000 words (text from the introduction to the conclusion, including references and figure legends)
- Abstract: Not applicable
- Authors: No more than 10; no more than two corresponding authors; no joint authorship permitted
- References: No more than 10
- Figures/Tables: One simple table (no larger than 1 page with 12-point Times New Roman font and 1-inch margins) OR one figure (in no more than two parts)
- Central Illustration: Not applicable
- Supplemental Material: Not permitted.
- Clinical Perspectives: Not applicable

RESEARCH LETTERS. Both Research Letters and Letters to the Editor are published under the heading “Letters.”

You may submit original research of a focused nature as a research letter.

- Word count: No more than 800 words, including references and figure legend
- References: No more than 5
- Authors: No more than 10; no joint authorship permitted; no joint corresponding authors
- Figures/Tables: One simple table (no larger than 1 page with 12-point Times New Roman font and 1-inch margins) OR one figure (in no more than two parts)
- Supplemental Material: Not permitted.
- Address the manuscript’s clinical question and findings with two bullets on the first page of your submission, totaling no more than 40 words:
 - What is the clinical question being addressed?
 - What is the main finding?

- **Ethical Approval:** Required. Please denote that your study received the proper ethical oversight in both your cover letter and the body of the article. For manuscripts reporting data on human subjects, note institutional review board/ethics committee approval (or formal review and exemption), including the specific name of the board or committee. For studies involving animal experiments, note that the study complied with all institutional and national requirements for the care and use of laboratory animals and, if applicable, received animal care and use committee approval. State the animal-handling protocol in the body of your article.

LETTERS TO THE EDITOR AND REPLIES. Focus on a specific manuscript that has appeared in *JACC*. Letters must be submitted within 3 weeks of the print issue date of the article. We will seek a reply to your letter from the authors of the original paper and publish the letter and the reply together, when possible. Letters may be submitted about Original Research articles only. *JACC* does not consider letters to the editors on review articles, editorials, or any correspondence, including research letters. Letters to the editor on guidelines are also no longer considered. Letters to the editor and replies are now published only in the online version of the journal and do not appear in print issues.

- **Word count:** No more than 400 words, including references and a figure legend, if applicable
- **References:** No more than 5
- **Figures/Tables:** 1 simple figure (in no more than 2 parts) or 1 simple table (no larger than 1 page with 12-point Times New Roman font and 1-inch margins)
- Please include the cited article as the first reference
- **Authors:** No more than 5; no joint authorship permitted; no joint corresponding authors
- **Title:** Unique title of 15 words or less that does not include the title of the Original Research paper
- **Title page:** Required

EDITORIAL COMMENTS. The editors invite all Editorial Comments published in the Journal. If you are invited to write an editorial, specific requirements will be sent to you. Please do not submit unsolicited editorials.

FELLOWS-IN-TRAINING & EARLY CAREER SECTION. These articles focus on topics that are specifically germane to FITs and early career cardiologists, and carry a maximum of 1,500 words and no more than three authors. The submissions must be substantive, engaging in hard-hitting topics. In terms of style, they must be formal in their presentation, as these are not blogs, and include citations (if relevant). We would encourage specificity when choosing a topic on which to write, as opposed to something that is too broad. All authors must be within 7 years of medical training. Please note that these articles will be reviewed and may be rejected by the *JACC* Editors. This content should now be submitted online at <https://www.jaccsubmit.org/>.

MANUSCRIPT ORGANIZATION

- **Cover Letter:** A short paragraph telling the editors why the authors think their paper merits publication may be included in the cover letter. Potential reviewers may be suggested in the cover letter, as well as reviewers to avoid. However, final reviewer assignment is determined by the editors.
- **Rebuttal Letter** (revisions or appeals only)
- **Manuscript file** (see individual manuscript types and Manuscript Content for specific formatting, and you may also email jacc@acc.org for a template on how to format your submission)
 - The entire manuscript (including tables) should be uploaded as a Microsoft Word document, with 1-inch margins and 12-point Times New Roman font. The title and abstract pages, including

keywords and abbreviations, should be single-spaced. All text (including tables) should be double-spaced. Page numbering should start with the title page.

- Page 1: Title page: See also Manuscript Content, below
- Page 2: Abstract, Condensed Abstract, Key Words, Abbreviations list
- Text
- Perspectives: Core Clinical Competencies and Translational Outlook implications (on a separate page after the conclusions, and only for Original Research submissions) OR Highlight bullet points (for review articles only)
- References
- Figure titles and captions, including a title and caption for the Central Illustration (if applicable)
- Tables, each on a separate page
- **Figures**
- **Supplemental material**

Please upload all supplemental materials, with the exception of videos, as one separately uploaded Word document, labeled Supplemental Material. This should include all supplemental text, tables and figures, figure legends, etc. If there are investigator names in the supplemental material that need to be captured as collaborators for PubMed, please indicate this in your Cover Letter.

MANUSCRIPT CONTENT

The order in which these items appear should also be the order in which they appear in your submission.

TITLE PAGE

- **Title** (no more than 15 words) and brief title of no more than 7 words
- **Authors' names** (including full first name, middle initial, last name, and degrees—MD, PhD, etc)
- **Total word count**
- **Departments and institutions** with which the authors are affiliated. Indicate the specific affiliations if the work is generated from more than one institution (use superscript letters ^a, ^b, ^c, ^d, and so on). List only the departments and institutions for co-authors.
- **Funding:** Information on grants, contracts, and other forms of financial support. List the cities and states of all foundations, funds, and institutions involved in the work.
- **Disclosures:** State each author's disclosures (or lack thereof). This must include the full disclosure of any relationship with industry. (See Relationship with Industry section.) If there are no relationships with industry, this should be stated.
- **Corresponding author contact information:** Under the heading, "Address for correspondence," provide the full name and complete postal address of the author to whom communications should be sent. Also provide telephone and fax numbers, an e-mail address, and an X (formerly Twitter) handle, if available. Please also provide a short tweet summarizing your paper on your title page. The tweet should be approximately 280 characters, including spaces. Please include up to 3 hashtags with your tweet (Example: #ACCIntl, #ACCFIT, #WomenInCardiology, #CVD, #HeartFailure). You may also review our hashtag guide (<https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/About-ACC/Social-Media/ACC-Social-Media-Hashtag-Reference-Guide.pdf>). Please note that the editors will review your content, and it may not ultimately be published on the @JACCJournals X (formerly Twitter) account. The corresponding author will be the sole contact for all submission queries.
- **Acknowledgements:** 100 words or less.

ABSTRACT. Provide a structured abstract of no more than 250 words for Original Research submissions, presenting essential data in 5 paragraphs introduced by separate headings in the following order: Background,

Objectives, Methods, Results, Conclusions. All data in the abstract also must appear in the manuscript text or tables. For general information on preparing structured abstracts, see “Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. *Ann Intern Med* 1990;113:69-76.”

An unstructured 150-word abstract should be provided for either type of review article.

KEYWORDS. Immediately after the abstract, provide a maximum of 6 key words, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, ‘and’, ‘of’). Be sparing with abbreviations. These key words will be used for indexing purposes, and therefore should be different than the terms/words already used in the title of the paper.

ABBREVIATIONS. Up to 10 abbreviations (eg, ECG, PTCA, CABG) or acronyms (GUSTO, SOLVD) may be listed. On a separate page following the abstract, list the selected abbreviations and their definitions (eg, TEE = transesophageal echocardiography). The editors will determine which lesser-known terms should not be abbreviated. Consult “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations),” available at www.icmje.org/recommendations, for appropriate use of units of measure.

TEXT. Use Times New Roman 12-point font. The text should be structured as: Introduction, Methods, Results, Discussion, and Conclusions. Use headings and subheadings in the Methods, Results, and, particularly, in the Discussion sections. **Every reference, figure, and table should be cited in the text in numerical order according to order of mention.**

CLINICAL PERSPECTIVES. The authors should delineate clinical competencies and translational outlook recommendations for their manuscripts. These competencies should not restate the questions underlying the work but describe the implications of the study and how the new information can be integrated into current practice based on the 6 domains delineated by the Accreditation Council on Graduate Medical Education (ACGME) and adopted by the American College of Cardiology Foundation (ACCF). These should be listed in the manuscript after the text and before the references. Please review the examples provided below. The competencies describe the implications of the study for current practice. The translational outlook places the work in a futuristic context, emphasizing directions for additional research.

CLINICAL COMPETENCIES. Competency-based learning in cardiovascular medicine addresses the 6 domains promulgated by the ACGME and endorsed by the American Board of Internal Medicine (Medical Knowledge, Patient Care and Procedural Skills, Interpersonal and Communication Skills, Systems-Based Practice, Practice-Based Learning, and Professionalism) (<http://www.acgme.org>). The ACCF has adopted this format for its competency and training statements, career milestones, lifelong learning, and educational programs. The ACCF also has developed tools to assist physicians in assessing, enhancing, and documenting these competencies (www.acc.org/education-and-meetings/products-and-resources/competencies). Authors are asked to consider the clinical implications of their report and identify applications in one or more of these competency domains that could be used by clinician-readers to enhance their competency as professional caregivers. This applies not only to physicians-in-training, but to the sustained commitment to education and continuous improvement across the span of their professional careers.

TRANSLATIONAL OUTLOOK. Translating biomedical research from the laboratory bench, clinical trials, or global observations to the care of individual patients can expedite discovery of new diagnostic tools and treatments through multidisciplinary collaboration. Effective translational medicine facilitates implementation of evolving strategies for prevention and treatment of disease in the community. The Institute of Medicine identified 2 areas needing improvement: testing basic research findings in properly designed

clinical trials and, once the safety and efficacy of an intervention has been confirmed, more efficiently promulgating its adoption into standard practice (Sung NS, Crowley WF, Genel M. The meaning of translational research and why it matters. *JAMA* 2008;299:3140-8). The National Institutes of Health (NIH) has recognized the importance of translational biomedical research, emphasizing multifunctional collaborations between researchers and clinicians to leverage new technology and accelerate the delivery of new therapies to patients (<https://ncats.nih.gov/translation>). Authors are asked to place their work in the context of the scientific continuum, by identifying impediments and challenges requiring further investigation and anticipating next steps and directions for future research.

CLINICAL TRIALS

EXAMPLE 1: For a Clinical Trial [*N Engl J Med* 2012;367:2375-84]:

PERSPECTIVES

Competency in Medical Knowledge: CABG surgery is the preferred method of revascularization for patients with diabetes and multivessel coronary artery disease.

Competency in Patient Care: The diabetic patient with coronary symptomatology, prior to the diagnostic catheterization, should be made aware that if multivessel disease is identified and intervention is indicated, surgical consultation should be entertained.

Translational Outlook 1: Although this is a relatively short-term study (median of 3.8 years), longer-term follow up of FREEDOM will lead to better understanding of the comparative benefit by CABG, specifically on mortality.

Translational Outlook 2: Compliance to medication is nonsatisfactory in patients with coronary artery disease. Comparing the compliance of FREEDOM patients taking a “polypill” approach (including aspirin, statin, and an angiotensin-converting enzyme inhibitor) with the compliance of patients treated conventionally with individual agents should be undertaken.

TRANSLATIONAL SCIENCE STUDIES

EXAMPLE 2: For a Translational Science Study [*Nat Med* 2014;20:215-9]:

PERSPECTIVES

Competency in Medical Knowledge: Inflammation is one of the major determinants of atherosclerotic plaque instability. Positron emission tomography with F18-labeled FDG has been employed for the identification of the macrophages in high-risk patients. Imaging with mannose, the isomer of glucose, may have an advantage because a subset of macrophages in high-risk plaques develop mannose receptors.

Translational Outlook 1: Although circulating biomarkers of inflammation, such as hs-CRP, provide reliable information of systemic inflammation, detection of inflammation at the plaque level may allow identification of the high-risk plaques.

Translational Outlook 2: Plaque imaging with sugars, although feasible, must in a randomized fashion investigate whether treatment of individual high-risk plaques would favorably influence major adverse outcomes in atherosclerotic disease.

REVIEW ARTICLE.

EXAMPLE 3: For a Review Article [*Lancet* 2014;383:955-62]:

PERSPECTIVES

Competency in Medical Knowledge 1: Selection of antithrombotic therapy for prevention of thromboembolism in patients with atrial fibrillation must consider several clinical factors, including the patient’s values and preferences.

Competency in Medical Knowledge 2: The oral direct thrombin inhibitor, dabigatran, and factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban

(so-called novel oral anticoagulants or NOACs) avoid the dietary restrictions and need for routine coagulation monitoring that are cumbersome aspects of anticoagulation with vitamin K antagonists such as warfarin.

Competency in Patient Care: All 3 NOACs currently approved for clinical use in the United States represent advances over warfarin because of their more predictable pharmacological profiles, fewer drug interactions, and considerably lower risk of intracranial bleeding than warfarin, but these advantages come at greater monetary cost, and there is presently no approved antidote or validated strategy rapid reversal of anticoagulation induced by any of the NOACs.

Competency in Interpersonal & Communication Skills: It is important to discuss the available options with patients who are candidates for the newer agents.

Translational Outlook 1: The mechanism by which each of the NOACs evaluated to date cause less intracerebral hemorrhage than well-managed warfarin anticoagulation requires further investigation.

Translational Outlook 2: Additional research is needed to understand the safety and efficacy of the NOACs, alone or in combination in patients with mechanical prosthetic heart valves to overcome the toxicity of this type of anticoagulation in the limited studies undertaken to date that contraindicate their use in patients who have undergone heart valve replacement with mechanical prostheses.

REFERENCES

- Cite references using superscript numerals without parentheses.
- The reference list should be double-spaced on pages separate from the text; references must be numbered consecutively in the order in which they are mentioned in the text. List all authors if 6 or fewer, otherwise list the first 3 and add “et al.” Do not use periods after author initials.
- Do not cite personal communications, manuscripts in preparation, preprint publications, or other unpublished data in the references; these may be cited in the text in parentheses, by name rather than by number. Do not cite abstracts that are older than 2 years. Identify abstracts by the abbreviation “abstr” in parentheses. If letters to the editor are cited, identify them with the word “letter” in parentheses. Websites must be cited as references.
- Use Index Medicus (National Library of Medicine) abbreviations for journal titles. It is important to note that when citing an article from the *Journal of the American College of Cardiology*, the correct citation format is *J Am Coll Cardiol*.
- Use the following style and punctuation for references:
 - Periodical. Do not use periods after the authors’ initials. Please provide all page numbers: Example: “5. Glantz SA. It is all in the numbers. *J Am Coll Cardiol*. 1993;21:835-837.”
 - DOI-based citation for an article in press.
 - If the ahead-of-print date is known, please provide. EXAMPLE: “16. Winchester D, Wen X, Xie L, et al. Evidence for pre-procedural statin therapy: meta-analysis of randomized trials. *J Am Coll Cardiol*. Published online Sept 28, 2010. <https://doi.org/10.1016/j.jacc.2010.09.028>”
 - If the ahead-of-print date is unknown, please omit. EXAMPLE: “16. Winchester D, Wen X, Xie L, et al. Evidence for pre-procedural statin therapy: meta-analysis of randomized trials. *J Am Coll Cardiol*. <https://doi.org/10.1016/j.jacc.2010.09.028>”
 - Chapter in book. Provide author(s), chapter title, editor(s), book title, publisher location, publisher name, year, and inclusive page numbers. EXAMPLE: “27. Meidell RS, Gerard RD, Sambrook JF. Molecular biology of thrombolytic agents. In: Roberts R, editor. *Molecular Basis of Cardiology*. Cambridge, MA: Blackwell Scientific Publications, 1993:295-324.”
 - Book (personal author or authors.) Provide a specific (not inclusive) page number. EXAMPLE: “23. Cohn PF. *Silent Myocardial*

Ischemia and Infarction. 3rd edition. New York, NY: Marcel Dekker, 1993:33.”

- Online media. Provide specific URL address and date information was accessed. EXAMPLE: “10. Henkel J. Testicular Cancer: Survival High With Early Treatment. *FDA Consumer magazine* [serial online]. January-February 1996. Accessed August 31, 1998. http://www.fda.gov/fdac/features/196_test.html.”
- Material presented at a meeting but not published. Provide authors, presentation title, full meeting title, meeting dates, and meeting location. EXAMPLE: “20. Eisenberg J. Market forces and physician workforce reform: why they may not work. Paper presented at: Annual Meeting of the Association of Medical Colleges; October 28, 1995; Washington, DC.”

FIGURE LEGENDS. Figure legends should be an in-depth explanation of each figure, including a figure TITLE and a CAPTION that includes the purpose of the figure, and brief method, results, and discussion statements pertaining to the figure. All abbreviations used in the figure should be identified either after their first mention in the legend or in alphabetical order at the end of each legend. All symbols used (arrows, circles, etc) must be explained. **Target length should be 50-100 words per figure, with the title no more than 10 words. Legends should not exceed 150 words.**

- All figures must have a number, title, and caption.
- Figures should be cited in numerical order in the text with each figure called out individually, rather than using a range (for instance, Figures 1, 2, and 3, rather than Figures 1-3).
- Supplemental figures should be cited as “Supplemental Figure 1, Supplemental Figure 2,” etc.
- Figure titles should be short and followed by a 2 to 3 sentence caption.
- Your Central Illustration, if not an existing figure, should be listed last.
- If the figure has been previously published, cite the figure source in the legend.

TABLES. Each table should be on a separate page, with the table number and title centered above the table and explanatory notes below the table. Use Arabic numbers. Table numbers must correspond with the order cited in the text. Tables should be self-explanatory, and the data presented in them should not be duplicated in the text or figures.

- All tables must have a title of up to 15 words.
- Each table may include a caption of up to 100 words. Abbreviations, which do not count toward the caption word limit, should be listed in a footnote under the table in alphabetical order.
- Footnote symbols should use lowercase, superscript letters, in alphabetical order: ^a, ^b, ^c, etc.
- If previously published tables are used, written permission from the original publisher (or copyright holder, if not the publisher) is required.
- Cite the source of the table in the footnote.

CENTRAL ILLUSTRATION. All Original Research manuscripts, *JACC* State-of-the-Art Reviews, and *JACC* Review Topics of the Week should develop at least 1 Central Illustration (that may be a hand-drawn figure), which summarizes the entire manuscript or at least a major section of the manuscript. Our in-house medical illustrators will create the final printable versions of these figures in consultation with the authors and the editors. The purpose of these illustrations is to provide a snapshot of your paper in a single visual, conceptual manner. Trial logos should not appear in Central Illustrations. The illustration should be labeled as “Central Illustration,” rather than as a numbered figure, and it must not duplicate content from other figures in the manuscript. This illustration must be called out in the body of the article. It must be accompanied by a legend (title and caption). The Central Illustration legend

should be listed last in your list of figure legends. For best practices on creating Central Illustrations, please see The Art and Challenge of Crafting a Central Illustration or Visual Abstract at <https://www.jacc.org/doi/full/10.1016/j.jacc.2019.10.035>.

FIGURES

- Figures and graphs should be provided in TIF format.
- Color and gray-scale images must be at least 300 DPI. Line art should be at least 1,200 DPI.
- All abbreviations used in the figure should be identified in alphabetical order at the end of each legend.
- All symbols used (arrows, circles, etc) must be explained.
- Figure legends should be double-spaced on pages separate from the text.
- Figure numbers must correspond with the order in which they are mentioned in the text.
- If previously published figures are used, written permission from the original publisher (or copyright holder, if not the publisher) is required. See STM Guidelines for details: <https://www.stm-assoc.org/intellectual-property/permissions/permissions-guidelines/>.
- If the figure has been previously published, cite the figure source in the legend.
- Do not include trial logos in figures.

Graphics software, such as Photoshop and Illustrator, should be used to create the art, but not presentation software such as PowerPoint, CorelDraw, or Harvard Graphics. Line art (black and white or color) and combinations of gray scale images and line art should be at least 1200 DPI. Lettering should be of sufficient size to be legible after reduction for publication. The optimal size is 12 points. Symbols should be of a similar size. Figures should be no smaller than 13 cm × 18 cm (500 × 700). Decimals, lines, and other details must be strong enough for reproduction. Use only black and white—not gray—in charts and graphs. Place crop marks on photomicrographs to show only the essential field. Designate special features with arrows. All symbols, arrows, and lettering on half-tone illustrations must contrast with the background. There is no fee for the publication of color figures. Our editors encourage authors to submit figures in color, as we feel it improves the clarity and visual impact of the images.

SUPPLEMENTAL MATERIAL

Supplemental material should be essential to the understanding and interpretation of the primary manuscript, and should contain original content that has not been previously published. The supplemental material will be posted online at the same time of publication of the article.

Please upload all supplemental materials, with the exception of videos and large data sets (see below), as one separately uploaded Word document that is labeled “Supplemental Material.” The pages of the Supplemental Material should be numbered consecutively. The first page of the Supplemental Material should list the title and page number of each element included in the document. Investigator names in a supplemental appendix will be included as collaborators by request and at the editor’s discretion.

The Supplemental Material document may include the following elements:

- Supplemental methods
- Supplemental results
- Supplemental tables (eg, Supplemental Table 1, Supplemental Table 2)
- Supplemental figures with accompanying figure legends (eg, Supplemental Figure 1, Supplemental Figure 2)
- All references that are cited within supplemental material should be placed in a separate reference section that is at the end of the supplemental material. The references should be formatted just as in the main manuscript and numbered and cited consecutively in the Supplemental Material.

All supplemental material will undergo editorial and peer review at the same time as the main manuscript is being evaluated. **Once the manuscript is accepted for final publication, the content of the supplemental material cannot be changed.**

LARGE DATA SETS

Large data sets for gene expression microarrays, SNP arrays, and high-throughput sequencing studies should be deposited in a public data repository (1,2). Microarray data must be deposited in a public data base that is compliant with Minimum Information About a Microarray Experiment (MIAME) guidelines (eg, GEO). High-throughput sequencing data must be deposited in a public data base that is compliant with Minimum Information About a Next-generation Sequencing Experiment (MINSEQE) guidelines. Please provide the relevant accession numbers in the text of the main manuscript.

1. Wheeler DL, Barrett T, Benson DA et al. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* 2007;35:D5-12.
2. Edgar R, Barrett T. NCBI GEO standards and services for microarray data. *Nat Biotechnol* 2006;24:1471-2.

VIDEOS

Inclusion of videos in the published paper is at the discretion of the Editors:

1. Video submissions for viewing online should be submitted as MP4 files only. The Journal office will not accept any other file formats.
2. Videos should be no larger than 15 MB. Larger videos will require longer download times and may have difficulty playing online.
3. A video legends page giving a brief description of the content of each video must be included in the manuscript. Please list the video legends page *immediately after* the figure legends page in the manuscript.
4. Authors should submit a thumbnail image for each video, cropped to W 200 X H 150, and uploaded as a tiff file.

EDITORIAL POLICIES

All manuscripts must be submitted online at <https://www.jaccsubmit.org>. By submitting an article to the journal, all authors of the submission agree to receive emails from all the American College of Cardiology’s JACC Journals regarding the manuscript, including editorial queries while the manuscript is under review and emails from the publisher should the paper be accepted for publication. The contact information provided by the corresponding author will be included in the galley proofs, the published PDF version of the manuscript, and the online version of the manuscript.

ETHICS. Manuscript submissions should conform to the guidelines set forth in the “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations),” available online at www.icmje.org/recommendations and most recently updated in May 2023.

Studies should be in compliance with human studies committees and animal welfare regulations of the authors’ institutions and the U.S. Food and Drug Administration guidelines. Human studies must be performed with the subjects’ written informed consent. Authors must provide the details of this procedure and indicate that the institutional committee on human research has approved the study protocol. If radiation is used in a research procedure, the radiation exposure must be specified in the Methods.

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. Patients have a right to privacy. Therefore, identifying information, including

patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes, and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian, next of kin, or other legally authorized representative). If consent is subject to conditions, the editorial office must be informed.

Written consents must be provided to the editorial office on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission. Animal investigation must conform to the "Position of the American Heart Association on Research Animal Use (<https://www.ahajournals.org/doi/abs/10.1161/01.hyp.7.4.655>)," adopted by the AHA on November 11, 1984. If equivalent guidelines are used, they should be indicated. The AHA position includes: 1) animal care and use by qualified individuals, supervised by veterinarians, and all facilities and transportation must comply with current legal requirements and guidelines; 2) research involving animals should be done only when alternative methods to yield needed information are not possible; 3) anesthesia must be used in all surgical interventions, all unnecessary suffering should be avoided and research must be terminated if unnecessary pain or fear results; and 4) animal facilities must meet the standards of the American Association for Accreditation of Laboratory Animal Care (AAALAC).

The *JACC* Journals have an ethics committee comprised of 7 members, which oversees quality control and will look into the issues of concern, if any.

EXCLUSIVE SUBMISSION/PUBLICATION POLICY. Manuscripts are considered for review only under the conditions that they are not under consideration elsewhere and that the data presented have not appeared on the Internet or have not been previously published (including symposia, proceedings, transactions, books, and articles published by invitation, and preliminary publications of any kind with the exception noted below and abstracts that do not exceed 400 words). On acceptance, transfer of copyright to the American College of Cardiology Foundation will be required. Elsevier will maintain copyright records for the College. Sharing of data from manuscripts that are under review or accepted but not yet published is expressly forbidden, unless permission is received from the *JACC* Editorial Office.

JACC does not consider the posting of manuscripts to a preprint server a prior publication if they have not undergone peer review and provided that the following conditions are met: 1) when submitting a manuscript to *JACC*, authors must acknowledge preprint server deposition and provide all associated accession numbers or DOIs; 2) versions of a manuscript that have been altered as a result of our peer review process may not be deposited; 3) the preprint version cannot have been indexed in MEDLINE or PubMed; and 4) upon publication in a *JACC* journal, authors are responsible for updating the archived preprint with a DOI and link to the published version of the article. Should the paper be accepted and published in a *JACC* journal, that *JACC* journal DOI should be considered to be the one representing this published work in all credits, citation, and attribution. Sharing of data from manuscripts that are under review or accepted but not yet published is expressly forbidden, unless permission is received from the *JACC* Editorial Office.

RELATIONSHIP WITH INDUSTRY POLICY. All authors are required to disclose any relationship with industry and other relevant entities-financial

or otherwise-within the past 2 years that might pose a conflict of interest in connection with the submitted article. All relevant relationships with industry, disclosures, and sources of funding for the work should be acknowledged on the title page, as should all institutional affiliations of the authors (including corporate appointments). This includes associations such as consultancies, stock ownership, or other equity interests or patent-licensing arrangements. If no relationship with industry exists, please state this on the title page.

All forms are now signed and submitted electronically. Once a manuscript is accepted, the authors will be sent links to complete the electronic Relationship with Industry forms. Elsevier now handles copyright for the journal. Only the corresponding author may electronically sign the copyright form; however, all authors are required to electronically sign a relationship with industry form. Once completed, a PDF version of the form is e-mailed to the author. Authors can access and confirm receipt of forms by logging into their account at <https://www.jaccsubmit.org>. Each author will be alerted if his or her form has not been completed by the deadline. Please note that copyright is now handled by the publisher and no copyright form will be sent to you until the manuscript has been sent to the publisher. Only authors appearing on the final title page will be sent a form. **YOU CANNOT ADD AUTHORS AFTER ACCEPTANCE OR ON PROOFS.**

The *JACC* Journals program prefers the term Relationships with Industry and Other Entities as opposed to the term Conflict of Interest, because, by definition, it does NOT necessarily imply a conflict. When all relationships are disclosed with the appropriate detail regarding category and amount, and managed appropriately for building consensus and voting, the *JACC* Journals program believes that potential bias can be avoided and the final published document is strengthened since the necessary expertise is accessible.

DISCLOSURE OF AI PROGRAMS. Please disclose in the cover letter and in the acknowledgement section (the latter of which is published, if the paper is accepted) if any artificial intelligence (AI) programs (e.g., ChatGPT, or other similar software) contributed to the compilation of the submitted manuscript as well as the nature of the contribution that the tool provided. This could include design, performance, analysis, writing, and reporting of the work.

REVIEW PROCESS. *JACC* uses a single-blind peer-review system, meaning that the authors are blinded to the identity of the reviewers and as a general rule, although there are exceptions, the reviewers are blinded to each other. While the *JACC* Associate Editor will be identified at the end of the review process, all correspondence concerning a manuscript should be addressed to the *JACC* editorial staff at jacc@acc.org. At initial submission, a manuscript is reviewed by editorial staff for compliance with journal style and to make sure the submission is clear and legible for reviewers and editors. Once the editorial staff have checked in the paper, it is assigned to the *JACC* Editor-in-Chief, who will assign it to an Associate Editor. The Associate Editor then determines if it should be sent for peer review or if it is not of sufficient priority for *JACC*. All reviewers and editors are asked to report any potential conflicts of interest, and when those exist the manuscript is reassigned to a different editor or reviewer. Once 2 reviews have been completed, the submission is reviewed by all *JACC* associate editors in a weekly meeting. The group then comes to one of the four decisions below:

- **Accept.** The manuscript is acceptable for publication in its current form. However, minor edits may be made by the *JACC* medical editors, illustrators, or the publisher, and authors will need to work with the appropriate contacts to ensure these changes are incorporated post-acceptance.
- **Minor Revision.** It is important to note that this decision does not guarantee acceptance. However, less significant edits are required than a Revision Required decision.

- **Revision Required.** The manuscript is unacceptable for publication in its current form. However, the editors are willing to reconsider a thoroughly revised manuscript. The authors must respond to all reviewer and editor comments and the submission will be re-reviewed and treated as a new submission.
- **Reject.** The manuscript is unacceptable for publication and/or is not an appropriate fit for *JACC*.

APEALS. Authors may appeal editorial decisions by email. To appeal a decision, send your rationale as to why the editors should reconsider the paper to jacc@acc.org. The rationale should address all of the reviewers' concerns. The editors may grant or deny the appeal, and their decision is final. Appeals must be submitted within 30 days of the date the decision was rendered.

PERMISSIONS. If a figure/table is reprinted or adapted from a previously published work, permission must be obtained from that publisher (or copyright holder, if not the publisher) and sent to the editorial office. Please also see Figures. If a manuscript includes excerpts of published text longer than 50 words, permission from the copyright holder to republish the text is required.

AUTHORSHIP. Each author must have contributed significantly to the submitted work. If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship. Each individual author should be listed on the title page and in the online submission system. If you have an author group, you may list it in a Supplemental Material. To save space, if group members have been previously published, the article should be referenced rather than reprinting the list of names. The editors consider authorship to include all of the following:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Participation solely in the collection of data does not justify authorship but may be appropriately acknowledged in the Acknowledgment section. Authors must also agree to the following statements. These questions will be part of the submission process and manuscripts will not be reviewed until they are confirmed: 1) the paper is not under consideration elsewhere; 2) none of the paper's contents with the exception of abstracts or preprint publications meeting journal requirements have been previously published; 3) all authors have read and approved the manuscript; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; 5) the full disclosure of any relationship with industry (see "Relationship with Industry Policy") or that no such relationship exists, is stated; and 6) the authors have provided both a central illustration and the perspectives (original research articles) or main messages (review articles). Exceptions must be explained.

EXPEDITED REVIEW. In order for Original Research submissions to be considered for expedited review, they should report important original findings of high-potential clinical impact or research significance. Authors should request expedited review and the rationale for this request in their cover letter at the time of submission. The editors commit to a decision regarding suitability for expedited publication processing within 2 days, and an initial decision within 14 days. Those manuscripts not deemed

appropriate for the expedited publication track will be considered according to the standard review process. We always inform authors whether we are able to offer expedited review. An agreement to provide expedited review does not guarantee acceptance.

STATISTICS. All publishable manuscripts will be reviewed for appropriateness and accuracy of statistical methods and statistical interpretation of results. We subscribe to the statistics section of the "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)," available at www.icmje.org/recommendations. In the Methods section, provide a subsection detailing the statistical methods, including specific methods used to summarize the data, methods used for hypothesis testing (if any), and the level of significance used for hypothesis testing. When using more sophisticated statistical methods (beyond t tests, chi-square, simple linear regression), specify the statistical package, version number, and nondefault options used. For more information on statistical review, see "Glantz SA. It is all in the numbers. *J Am Coll Cardiol*. 1993;21:835-7."

PATIENT CONSENT. Publication of any individually identifiable information about a living individual requires a written consent under HIPAA known as a "HIPAA authorization" from the individual or the individual's guardian. Written consent may also be required under other federal, state, local or international laws. These consents are referred to herein globally as "consents." While consents cannot be uploaded in the ACC submission site, authors are required to obtain them where necessary and to document in the submission data that they were obtained. ACC requires that authors obtain any necessary consents before initial submission to avoid delays if the submission is accepted for publication. Additionally, if a submission is accepted, authors will have to sign a form confirming they have obtained all necessary consents. The authors of each submission are fully responsible for obtaining any necessary consents.

Additionally, if you are conducting research on human subjects you are required to obtain: (1) institutional review board approval and (2) (a) informed consent or (b) a waiver of informed consent in accordance with applicable law. Such institutional review board approval must be completed prior to commencement of the research. The author's submission should clearly articulate the institutional review board's determination as to whether informed consent was required or waived. If the consent is subject to conditions, please inform ACC upon submission of your paper. In certain scenarios, the institutional review board or your institution may determine that the research is exempt and oversight is not required in accordance with applicable law and institutional policy. If so, the exemption must be documented in the submission.

Individual's privacy is paramount to ethical research. Therefore, identifying information, including individuals' names, initials, hospital numbers, and images should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and only the minimum necessary identifiable information is articulated in the research.

Even where consent/ authorization has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide an assurance that alterations do not distort scientific meaning.

Unless individually identifiable information is essential, all submissions should be de-identified and anonymized in accordance with applicable international, federal, state and local laws. As stated above you are responsible for obtaining all necessary HIPAA authorizations and consents under applicable law, including but not limited to obtaining permissions to de-identify and anonymize information included in the submission in instances where information will be included from deceased individuals, consents should be

obtained from the deceased individual's next of kin or legal representative in accordance with applicable law.

MENTIONING BRAND NAME DRUGS/DEVICES. Please reduce or remove mentions of brand name/trademarked drugs and devices from the manuscript. In particular, we try to avoid using brand name/trademarked drugs and devices in titles. Note that if the manuscript is offering CME, we cannot discuss brand name drugs/devices at all.

If you are reproducing an image of a device, permission from the device manufacturer is the sole responsibility of the authors. You will not be asked to provide the permission, but the journal/Elsevier will assume that you have obtained permission at the point of acceptance.

RESEARCH DATA. This journal encourages and enables you to share data that supports your research publication where appropriate and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project. For more information on depositing, sharing and using research data and other relevant research materials, visit the [Research Data page](#).

Data Statement

To foster transparency, we encourage you to state the availability of your data in your submission. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. For more information, visit the [Data Statement page](#).

REPORTING SEX- AND GENDER-BASED ANALYSES

REPORTING GUIDANCE. For research pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the [Sex and Gender Equity in Research \(SAGER\) guidelines](#) and the [SAGER guidelines checklist](#). These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation—however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

DEFINITIONS. Sex generally refers to a set of biological attributes that are associated with physical and physiological features (eg, chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men, and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have

differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the [resources on this page](#) offer further insight around sex and gender in research studies.

ELSEVIER POLICIES

This journal offers authors a choice in publishing their research:

OPEN ACCESS

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access fee is payable by authors or on their behalf, eg, by their research funder or institution.

SUBSCRIPTION

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards. For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#).

OPEN ACCESS FEE. The open access fee for Original Research publications is \$6,825, excluding taxes. Learn more about [Elsevier's pricing policy](#). Please contact the [editorial office](#) for rates for other types of articles.

FUNDING BODY AGREEMENTS AND POLICIES

CC BY for funded authors only

Elsevier has established a number of agreements with funding bodies, which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

CC_BY-NC-ND

CC BY-NC-ND license

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

REUSE OF JACC MATERIAL. No part of materials published in *JACC* may be reproduced without written permission of the publisher. You may be able to obtain permission to republish content for individual articles through RightsLink. Some materials qualify for gratis usage. See STM Guidelines for details: <https://www.stm-assoc.org/intellectual-property/permissions/permissions-guidelines>. Permission may be sought directly from Elsevier's Global Rights Department. Phone: (215) 239-3804 or 44-1865-843-830. Fax: 44-1865-853-333. Requests also may be completed online via the Elsevier site: <https://www.elsevier.com/authors/permission-request-form>.

JACC JOURNALS PUBLICATION INTEGRITY GUIDELINES

JACC Journals have adopted integrity guidelines to help authors uphold the ethics, values, and principles of the publication process at the highest standards. The guidelines below include best practices and are consistent with those implemented by other journals and scientific publishers.

Plagiarism

The Office of Research Integrity (ORI) defines plagiarism as “theft or misappropriation of intellectual property and the substantial unattributed textual copying of another’s work.” Manuscripts where unacknowledged copying of others’ ideas, language and/or results will not be published in *JACC Journals* and, depending on level of egregiousness, will be reported to ORI and/or other agencies. Therefore, authors should ensure that appropriate attribution and citation is provided when discussing, paraphrasing, or summarizing the work of others. Included is the use of one’s own text from previous publications (exclusive of materials and methods), where appropriate attribution and citation is necessary. Reuse of one’s own or others’ previously published data, whether it be publishing the same paper in multiple journals or adding incremental new data to a previous publication without providing appropriate references, will be considered a duplicate publication.

Should *JACC Journals* discover acts of plagiarism pre-publication, the publication process will be halted until the matter is resolved. Should *JACC Journals* discover acts of plagiarism post-publication, an investigation to determine the extent and context of the plagiarism will be conducted. *JACC Journals* reserve the right to correct or retract any publication based on the findings of said investigations.

Due credit for unpublished and published work

Authors must discuss, properly cite, and provide appropriate permissions for any unpublished work included in submitted manuscripts. Any data, intellectual contribution, and/or technical development, including unpublished data from databases, must be acknowledged and appropriately cited. Authors must include written assurance that they are complying with the data-licensing agreements of the original source documents when using licensed data. If an author is reusing or modifying previously published or copyrighted figures, documented permission from the previous publisher or copyright holder is required.

Duplicate publication

Material submitted to a *JACC Journal* must be original. Submitted material cannot have been previously published and cannot be simultaneously submitted elsewhere (exclusive of meeting abstracts). Related manuscripts under consideration or in press elsewhere must be declared by authors submitting to a *JACC Journal* at the time of submission in the cover letter. If related material is submitted elsewhere after submission to a *JACC Journal*, authors must notify the *JACC Journal* immediately.

Data integrity

All data and figures published in *JACC Journals* must accurately represent the original data and findings. Misrepresentation of data acquisition and/or post-acquisition processing is not acceptable.

While *JACC Journals* understand minor data processing may be unavoidable, submitted digital images must be as close to original as possible. Processing/image adjustment (eg, contrast or brightness) must be applied equally across the entire image and any relevant controls. Any image processing/adjustment should not make data disappear or mask additional bands. Authors should explain any image alterations in the figure legend and identify image acquisition tools and processing software in the methods. Integral settings and processing manipulations used to process the presented data should also be described.

JACC Journals reserve the right to request all unprocessed data files included in a submitted manuscript. Manuscript evaluation may be halted or discontinued if the files are not available upon request.

Authors should take care to adhere to the following specific concerns:

Electrophoretic gels and blots. Cropped gels must preserve all important bands. Individual images cannot be used in multiple figures except when the figures describe different aspects of the same experiment (eg, when a single control experiment serves multiple experiments performed simultaneously). When an image is used in multiple figures, authors must clearly state the reason(s) for this in the figure legend.

Quantitative comparisons between samples on different gels/blots should be avoided, and only performed when normalizing controls are available for both gels. Protein loading controls must be run on the same blot. If unavoidable, the figure legend must indicate that the samples are derived from the same or parallel experiments and that the gels/blots are processed in parallel.

Removal of irrelevant or blank lanes from a gel is permissible; however, such alterations must be noted in the figure legend and boundaries between the nonadjacent or rearranged lanes must be clearly marked in the figure.

Microscopy. A scale bar should be included with all microscopy images. The measured resolution at which an image was acquired and any subsequent processing or averaging that enhances the resolution must be clearly stated. Adjustments should be applied over the entire image.

Microscopy settings for comparable controls and samples should be the same between experiments. Any necessary nonlinear, pseudocolor, or color adjustments made to images must be stated in the figure legend. Any manipulation of threshold and expansion or contraction of signal ranges should be avoided.

Authors should not combine images obtained separately, at different times, or from different locations, into a single image, unless specifically stated in the figure legend.

Data Visualization Guidelines. Figures representing data need to be designed and presented in a way that allows readers to understand and critically interpret the data. Authors must ensure that figures use easily distinguishable colors/lines/symbols and are color-blind-safe.

Continuous data and small sample sizes should be represented with figures that show full data distribution, such as dot or scatter plots. Bar graphs should be avoided except when showing counts or proportions.

Authors should consider adding a flow chart or study design diagram when appropriate. Flow charts should provide information about excluded observations and reasons for exclusion at each phase of the study.

Data Management Guidelines. As outlined by ORI, data management is one of the essential areas of responsible conduct of research (<https://ori.hhs.gov/education/products/clinicaltools/data.pdf>). Authors are expected to maintain all of the primary data used for their research submission, so that it can be evaluated by the reviewers and editors. At a minimum the retention of data after manuscript publication should conform to the policies within the authors’ organization and the funding organization.

CONTACTING US

EDITORIAL OFFICE AT HEART HOUSE. For enquiries relating to submitted articles or to articles currently under review, please contact the *JACC* editorial office at jacc@acc.org. All manuscripts must be submitted online at www.jaccsubmit.org. Authors who are having trouble may e-mail jacc@acc.org or call the number below.

The mailing address for the *JACC* editorial office and the Editor-in-Chief is:
Valentin Fuster, MD, PhD, MACC
Editor-in-Chief, *Journal of the American College of Cardiology*
Heart House, 2400 N Street NW
Washington, DC, 20037
Phone: (202) 375-6136
Fax: (202) 375-6819

Updated March 1, 2024

ELSEVIER (PUBLISHER). For information on articles that have been accepted for publication, please visit Elsevier's Authors Home at <https://www.elsevier.com/researcher/author>. Elsevier's Authors Home also provides the facility to track accepted articles (<http://www.elsevier.com/trackarticle>) and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information, frequently asked questions, and more. You are also welcome to contact Customer Support via https://service.elsevier.com/app/contact/flow_id/3/supporthub/publishing/. Authors can order copies of the issue in which their article appears at a discounted rate. For this service, please contact:

Elsevier Health Sciences Division

Subscription Customer Service

3251 Riverport Lane

Maryland Heights, MO 63043

Tel: 1-800-654-2452

E-mail: journalscustomerservice-usa@elsevier.com.

English language help service: Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (before submission). Please visit <https://webshop.elsevier.com/language-editing/> for further information.